- The disease
- Cognitive impairment covers a spectrum of conditions in which memory, attention, processing speed, or executive function decline below expected levels. It is a primary endpoint or safety measure in a wide range of clinical trials, from Alzheimer's disease and Parkinson's disease to anaesthesia recovery and neurological disorders. Detecting subtle cognitive change reliably and repeatedly is a central methodological challenge in these trials. Standardised, validated assessment tools are used to measure cognitive performance at multiple timepoints across trial participants.
- What the asset is trying to do
- The Cogstate Brief Battery is a computerised cognitive assessment tool, classified as a diagnostic device rather than a drug or biologic. It presents card-game style tasks on a screen to measure speed and accuracy across cognitive domains including psychomotor function, attention, visual learning, and working memory. Because it uses novel stimuli at each administration, it is designed to reduce practice effects compared with traditional paper-based tests. The battery has been deployed as an outcome measure in third-party-sponsored clinical trials, as evidenced by its use in completed and active studies listed on ClinicalTrials.gov.
- What the trial is measuring, and why it matters
- As a cognitive assessment tool used within other sponsors' trials, the Cogstate Brief Battery is not itself the subject of a single lead interventional trial with a defined primary endpoint in the conventional sense. In the trials listed, it serves as a measurement instrument for cognitive outcomes. Relevant metrics typically captured by such tools include composite cognitive scores, domain-specific accuracy and speed scores, and change from baseline over the trial duration. The clinical relevance of these metrics is that regulators and sponsors require validated, sensitive measures of cognitive change to support efficacy and safety claims in central nervous system (CNS) drug development.
- Efficacy benchmarks in this setting
- Approved cognitive assessment instruments used in Alzheimer's disease trials include the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) and the Clinical Dementia Rating-Sum of Boxes (CDR-SB). In the lecanemab Phase 3 trial (CLARITY AD), the treatment group showed a 0.45-point difference on CDR-SB versus placebo at 18 months (van Dyck et al, New England Journal of Medicine, 2023). In the donanemab Phase 3 trial (TRAILBLAZER-ALZ 2), the treatment group showed a 35% slowing of decline on the Integrated Alzheimer's Disease Rating Scale (iADRS) versus placebo (Sims et al, JAMA, 2023). The Cogstate Brief Battery is a measurement instrument rather than a therapeutic, so direct efficacy comparisons to drug trial outcomes are not applicable; the figures above are provided as context for the cognitive trial landscape in which the battery is deployed.
- Commercial context
- The Cogstate Brief Battery is a commercially available, approved cognitive assessment product and is not in clinical development as a new therapeutic or device seeking first regulatory clearance. Cogstate Ltd (ASX: CGS) discloses revenue from its clinical trials technology segment, which includes use of the battery in sponsor-funded trials. Recent ASX announcements include an on-market share buyback and investor webinar materials dated May-June 2026, but no specific financial figures, partnership terms, or deal values are available in the provided input to cite. The trials listed on ClinicalTrials.gov in which the battery appears as a measurement tool span indications including Parkinson's disease, Lewy body dementia, Tourette syndrome, multiple sclerosis, and anaesthesia recovery, illustrating the breadth of its deployment across third-party sponsors.